The Effect of Two Different Oral Care Solutions on Ventilator-Associated Pneumonia and Oral Health of Mechanically Ventilated Patients in the Intensive Care Unit
Launched by SAGLIK BILIMLERI UNIVERSITESI · May 4, 2025
Trial Information
Current as of November 07, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a randomized, double-blind study in adults in the intensive care unit who need mechanical ventilation (breathing machines). It compares two daily mouth-care routines to see if they reduce ventilator-associated pneumonia (VAP) and improve oral health. One group uses 0.25% chlorhexidine (a common antiseptic) and the other uses 0.05% cetylpyridinium chloride. Care includes brushing the teeth twice daily and cleaning the mouth with the assigned solution four times a day for five days, with nurses checking oral health each morning and a specialist checking for pneumonia on days 1, 3, and 5.
To be eligible, adults aged 18 to 90 must be on a ventilator for at least 48 hours and not already have pneumonia or COVID at the start, with a CPIS score under 6 on day 1, no facial or mouth trauma, and no allergy to the mouth-care solutions. Informed consent is obtained from patients or their families. The trial is currently enrolling, with about 60 participants planned, and results aren’t available yet. The study aims to determine which mouth-care solution better prevents pneumonia and supports better oral health in these high-risk patients.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria:• Being 18 years of age or older
- • Requiring mechanical ventilation for at least 48 hours
- • Not having a diagnosis of aspiration pneumonia
- • Having a Clinical Lung Infection Score (CPIS) \<6 on the first day
- • Not having a diagnosis of pneumonia or COVID
- • Not having facial or oral trauma
- • Being within the first 24 hours of the intubation process
- • Not having a medical impediment to elevating the head of the bed 30o
- Exclusion Criteria:
- • Not accepting to participate in the study
- • Termination of MV support for less than 48 hours
- • Being allergic to any of the solutions to be used in oral care
- • Being diagnosed with immunodeficiency
- • Having thrombocytopenia, leukopenia and oral aphthae, stomatitis, candidiasis, gingivitis
- • Using immunosuppressive drugs
About Saglik Bilimleri Universitesi
Saglik Bilimleri Universitesi, or the University of Health Sciences, is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university focuses on translating scientific discoveries into practical applications that enhance patient care and public health outcomes. Its commitment to rigorous ethical standards and comprehensive training equips researchers and healthcare professionals to contribute effectively to the global medical community. Through its clinical trial initiatives, Saglik Bilimleri Universitesi aims to address pressing health challenges and foster the development of new therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, Turkey
Patients applied
Trial Officials
bediye öztaş
Principal Investigator
Saglik Bilimleri Universitesi
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported